ChemicalBook >> journal list >> Biochemical Genetics >>article
Biochemical Genetics

Biochemical Genetics

IF: 1.6
Download PDF

LncRNA SNHG16 Drives PD-L1-Mediated Immune Escape in Colorectal Cancer through Regulating miR-324-3p/ELK4 Signaling.

Published:17 December 2024 DOI: 10.1007/s10528-024-11000-3 PMID: 39688781
Zhiyuan Chen, Zhenjuan Wu, Minghao Wu, Yu Zhang, Sha Hou, Xiangyang Wang, Ya Peng

Abstract

Colorectal cancer (CRC) is a common malignancy that claims the life of many patients. Nucleolar RNA host gene 16 (SNHG16) has been identified as an oncogene in CRC development. However, the role and mechanism of SNHG16 in CRC remain unclear. A total of 27 cases of CRC tumor tissues and adjacent tissues were collected to investigate the expression and correlation among SNHG16, miR-324-3p, ELK4 and PD-L1 using qRT-PCR, western blot and Pearson analysis. Cell proliferation, migration and invasion abilities were determined using CCK-8 and transwell assays. The cytotoxicity of CD8 + T cells and the apoptosis of CD8+ T cells was evaluated by LDH assay and flow cytometry, respectively. Dual luciferase assay, RIP and ChIP methods were performed to verify molecular interactions. Our results showed that SNHG16, ELK4 and PD-L1 expression were abnormally elevated and miR-324-3p expression was decreased in tumor tissues from CRC patients and CRC cells. SNHG16 silencing resulted in suppression of cell growth, metastasis, and immune escape of CRC cells, which was reversed by miR-324-3p inhibitor and ELK4 overexpression. Mechanistically, SNHG16 acted as a competitive endogenous RNA to enhance ELK4 expression by sponging miR-324-3p, thereby provoking the transcription of PD-L1. Our results demonstrated that SNHG16 silencing led to the suppression of cell growth, metastasis, and immune escape of CRC cells through mediating miR-324-3p/ELK4/PD-L1 axis, offering promising targets for CRC treatment.

Substances (4)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Atezolizumab 1380723-44-3 117 suppliers Inquiry
Atezolizumab 1380723-44-3 117 suppliers Inquiry
Atezolizumab 1380723-44-3 117 suppliers Inquiry
Atezolizumab 1380723-44-3 117 suppliers Inquiry

Similar articles

IF:4.5

Antimicrobial agent chloroxylenol targets β‑catenin‑mediated Wnt signaling and exerts anticancer activity in colorectal cancer.

International journal of oncology Qi Sun, Boxin Liu,etc Published: 1 November 2023
IF:3

MiR-23a-3p targets PTEN as a novel anti-ferroptosis regulator in Fuchs endothelial corneal dystrophy

Experimental eye research Miaomiao Chi, Yaning Zhao,etc Published: 22 November 2024
IF:5.4

Sodium butyrate in both prevention and supportive treatment of colorectal cancer.

ACS Applied Energy Materials Karolina Kaźmierczak-Siedlecka, Luigi Marano,etc Published: 26 October 2022